Tags : Insud

Insights+ Key Biosimilars Events of February 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence providers are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More